Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus CLINDA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus CLINDA DERM.
BENZAMYCIN vs CLINDA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces).
Category C
Category C
Topical Antibiotic
Topical Antibiotic